Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2000-09-14
2004-01-06
Eyler, Yvonne (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C435S007210, C530S350000, C530S324000, C514S002600
Reexamination Certificate
active
06673352
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This application is directed generally to methods of treating prostate cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.
2. Related Art
Mullerian inhibiting substance (MIS) is a member of the transforming growth factor-&bgr; (TGF&bgr;) family of growth and differentiation factors. After the sexually indifferent gonad commits to testis development under the influence of the testis-determining factor, SRY, Sertoli cells of the fetal testis begin procuring MIS, which is a phenotypic hallmark of testis development (Swain et al.,
Nature
391:761-767 (1998)). MIS, also known as anti-Mullerian hormone (Jossa et al.,
Recent Prog. Horm. Res.
48: 1-59 (1993)), is absolutely required for normal male reproductive tract development because it affects the regression of the Mullerian duct of the bipotential urogenital ridge, which, is left undisturbed, would give rise to female reproductive tract structures such as the uterus, Fallopian tubes, and upper vagina (Jost, A.,
Arch. Anal. Microsc. Morphol. Exp.
36:271-315 (1947); Cate et al.,
Cell
45:685-698 (1986); Teixeira and Donohoe,
J. Androl.
17:336-341 (1996)). Adult ovaries and testes also produce MIS, albeit at much lower levels than in fetal males, and the functional roles played by MIS in these settings have not been fully elucidated (Ueno et al.,
Endocrinology
123:1652-1659 (1988); Tsafriri et al.,
Biol. Reprod.
38:481-485 (1988)). However, studies in the rat suggest a role for MIS in oocyte maturation (Takahashi et al.,
Mol. Cell Endocrinol.
47:225-234 (1986)) and in human ovary in blocking granulosa cell proliferation and reducing steroidogenesis (Kim et al.,
J. Clin. Endocrinol. Metab.
75:911-917 (1992), Seifer et al.,
J. Clin. Endocrinol. Metab.
76:711-714 (1993)).
SUMMARY OF THE INVENTION
The present invention provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of MIS to a patient.
The present invention also provides a method of treating a condition or disease characterized by an excess of one or more androgens, the method comprising administering an effective amount of a nucleic acid encoding MIS to a patient.
The present invention also provides a method of decreasing the plasma level of one or more androgens, the method comprising administering to a patient an effective amount of MIS, wherein the amount of MIS is sufficient to decrease the plasma level of the one or more androgens below the normal level for the one or more androgens.
The present invention also provides a method of decreasing the plasma level of one or more androgens, the method comprising administering to a patient an effective amount of nucleic acid encoding MIS, wherein the amount of MIS is sufficient to decrease the plasma level of the one or more androgens below the normal level for the one or more androgens.
The methods of the present invention are particularly well-suited for the treatment of prostate cancer, polycystic ovarian disease, benign prostatic hypertrophy, and precocious puberty.
REFERENCES:
patent: 4404188 (1983-09-01), Donahoe et al.
patent: 4487833 (1984-12-01), Donahoe et al.
patent: 4753794 (1988-06-01), Donahoe
patent: 5010055 (1991-04-01), Donahoe
patent: 5011687 (1991-04-01), Donahoe et al.
patent: 5110904 (1992-05-01), Haviv et al.
patent: 5198420 (1993-03-01), Donahoe et al.
patent: 5310880 (1994-05-01), Donahoe et al.
patent: 5359033 (1994-10-01), Cate et al.
patent: 5427780 (1995-06-01), Cate et al.
patent: 5484768 (1996-01-01), Donahue et al.
patent: 5538892 (1996-07-01), Donahoe et al.
patent: 5547854 (1996-08-01), Donahoe et al.
patent: 5661126 (1997-08-01), Donahoe et al.
patent: 5906979 (1999-05-01), Allan
patent: 5912224 (1999-06-01), Donahoe et al.
patent: WO 89/06695 (1989-07-01), None
patent: WO 95/16709 (1995-06-01), None
Shaw, M.A. et al., “Aminoglutethimide and Ketoconazole: Historical Perspectives and Future Projects,”J. Steroid Biochem. 31:137-146, Pergamon Press plc (1988).
Sonino, N., “The Use of Ketoconazole as an Inhibitor of Steroid Production,”New England J. Med. 317:812-818, The Massachusetts Medical Society (1987).
Barrie, S.E. et al., “Biochemistry and Pharmacokinetics of Potent Non-steroidal Cytochrome P45017&agr;Inhibitors,”J. Steroid Biochem. Molec. Biol. 60:347-351, Elsevier Science Ltd. (1997).
Nnane, I.P. et al., “Inhibition of Androgen Synthesis in Human Testicular and Prostatic Microsomes and in Male Rats by Novel Steroidal Compounds,”Endocrinol. 140:2891-2897, The Endocrine Society (Jun. 1999).
International Search Report for International Application No. PCT/US00/25094, mail Jan. 4, 2001.
J. Cell. Biochem. (Supplement 12A):183, UCLA Symposia on Molecular & Cellular Biology, Alan R. Liss, Inc. (1988).
J. Cell. Biochem. (Supplement 16B):123, Keystone Symposia on Molecular & Cellular Biology, Wiley-Liss, Inc. (1992).
J. Cell. Biol. 115(3, Part 2):276a, Rockefeller University Press (1991).
Baarends, W.M. et al., “A novel member of the transmembrane serine/threonine kinase receptor family is specifically expressed in the gonads and in mesenchymal cells adjacent to the mülllerian duct,”Development120:189-197, The Company of Biologists Limited (1994).
Baker, M.L. and Hutson, J.M., “Serum Levels of Mullerian Inhibiting Substance in Boys throughout Puberty and in the First Two Years of Life,”J. Clin. Endocrinol. Metabol. 76:245-247, The Endocrine Society (1993).
Bardin, C.W. et al., “Androgens,” inReproductive Endocrinology, Surgery and Technology, vol. 1, Adashi, E.Y. et al., eds., Lippincott-Raven, Philadelphia, pp. 505-525 (1995).
Behringer, R.R. et al., “Abnormal sexual development in transgenic mice chronically expressing Müllerian inhibiting substance,”Nature345:167-170, Macmillan Journals (1990).
Behringer, R.R. et al., “Müllerian-Inhibiting Substance Function during Mammalian Sexual Development,”Cell79:415-425, Cell Press (1994).
Cate, R.L. et al., “Isolation of the Bovine and Human Genes for Müllerian Inhibiting Substance and Expression of the Human Gene in Animal Cells,”Cell45:685-698 (1986).
Cate, R.L. et al., “Development of Mullerian Inhibiting Substance as an Anti-cancer Drug,”Cold Spring Harbor Symposia on Quantitative Biology, vol. LT:641-647, Cold Spring Harbor Laboratory (1986).
Chin, T. et al., “Human Müllerian Inhibiting Substance Inhibits Tumor Growth in Vitro and in Vivo,”Cancer Res. 51:2101-2106, American Association for Cancer Research (1991).
Crowley, W.F. et al., “Neuroendocrine & Gonadal Control Of Male Reproduction,” application for National Institute of Child Health and Human Development grant No. 2. U54 HD-28138-10 (Apr. 1, 2000 or later).
di Clemente, N. et al., “Cloning, Expression, and Alternative Splicing of the Receptor for Anti-Müllerian Hormone,”Mol. Endocrinol. 8:1006-1020, The Endocrine Society (1994).
Donahoe, P.K. et al., “A Graded Organ Culture Assay for the Detection of Mullerian Inhibiting Substance,”J. Surg. Res. 23:141-148, Academic Press, Inc. (1977).
Donahoe, P.K. et al., “Mullerian Inhibiting Substance Inhibits Growth of a Human Ovarian Cancer in Nude Mice,”Ann. Surg. 194:472-480, J.B. Lippincott Company (1981).
Donahoe, P.K., “Müllerian Inhibiting Substance in Reproduction and Cancer,”Mol. Reproduct. Develop. 32:168-172, Wiley-Liss, Inc. (1992).
Donahoe, P.K. et al., “MIS Receptors-Novel Serine/Threonine Kinase Components,” application for National Institute of Child Health and Human Development grant No. 2 R01 HD-32112-06A1 (Jan. 15, 2000 or later).
Fuller, Jr., A.F. et al., “Mullerian Inhibiting Substance Reduction of Colony Growth of Human Gynecologic Cancers in a Stem Cell Assay,”Gynecol. Oncol. 22:135-148, Academic Press, Inc. (1985).
Fynn-Thompson, E., “Müllerian Inhibiting Substance Regulates Steroidogenesis in Rodent Leydig Tumor Cell Lines,” Slides Presented at Harvard Medical School Prematriculation Summer Program Presentation, 13 pages (Aug. 1998).
Hudson, P.L. et al., “An Immunoassay to Detect Human Mullerian Inhibiting Substanc
Donahoe Patricia K.
Fynn-Thompson Eric
Teixeira Jose
Andres Janet L.
Eyler Yvonne
The General Hospital Corporation
LandOfFree
Use of Mullerian inhibiting substance for treating excess... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of Mullerian inhibiting substance for treating excess..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of Mullerian inhibiting substance for treating excess... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3245694